Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa
Yoel Lubell, Arthorn Riewpaiboon, Arjen M Dondorp, Lorenz von Seidlein, Olugbenga A Mokuolu, Margaret Nansumba, Samwel Gesase, Alison Kent, George Mtove, Rasaq Olaosebikan, Wirichada Pan Ngum, Caterina I Fanello, Ilse Hendriksen, Nicholas PJ Day, Nicholas J White & Shunmay Yeung
Volume 89, Number 7, July 2011, 504-512
Table 3. Mortality and incidence of moderate or severe neurological sequelae
| Parameter | Quinine | Artesunate |
|---|---|---|
| Mortality | 297/2713 (10.9%) | 230/2712 (8.5%) |
| Severe neurological sequelae | 21/2713 (0.8%) | 22/2712 (0.8%) |
| DALYs | 3 (95% PI: 2.4–4.6) | 2.3 (95% PI: 1.9–2.6)a |
| Incremental DALYs averted with the use of artesunate | – | 0.7(95% PI: 0.2–1.3)a |
| Incremental number needed to treat (with artesunate) to avert 1 death | – | 41 (95% CI: 25–112) |
CI, confidence interval; DALY, disability-adjusted life year; PI, percentile interval.
a The 95% PI represents the interval between the 2.5% and 97.5% percentiles.